Skip to main content
Premium Trial:

Request an Annual Quote

BGI Extends Expiration Date for Complete Genomics Tender Offer, Gets China OK

NEW YORK (GenomeWeb News) – Complete Genomics said in a filing with the US Securities and Exchange Commission today that BGI-Shenzhen's tender offer to acquire the firm has been extended to midnight, New York City time, on Jan. 18.

The $118 million bid, which was launched in September, was scheduled to expire at midnight last Friday. Complete Genomics said that as of the close of business on Jan. 11, approximately 29.3 million shares representing around 83 percent of its outstanding common stock had been validly tendered and not withdrawn.

Complete Genomics also said in the SEC filing that the National Development and Reform Commission of the People's Republic of China had granted clearance of the proposed acquisition last Friday. The deal passed US Federal Trade Commission review last week.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.